Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
BackgroundKnowing about cytokine profile contributes to clarify the underling immune mechanism of HBsAg seroclearance rate increase. This study aims to investigate cytokine changes during nucleos(t)ide analogues (NAs) and peginterferon-α (Peg-IFNα) therapy and their impact on the HBsAg serologic res...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1104329/full |
| _version_ | 1797961026971369472 |
|---|---|
| author | Peipei Wang Peipei Wang Peipei Wang Zhishuo Mo Zhishuo Mo Zhishuo Mo Ying Zhang Ying Zhang Ying Zhang Chunxia Guo Trevor Kudzai Chikede Dabiao Chen Dabiao Chen Dabiao Chen Ziying Lei Ziying Lei Ziying Lei Zhiliang Gao Zhiliang Gao Zhiliang Gao Qian Zhang Qiaoxia Tong |
| author_facet | Peipei Wang Peipei Wang Peipei Wang Zhishuo Mo Zhishuo Mo Zhishuo Mo Ying Zhang Ying Zhang Ying Zhang Chunxia Guo Trevor Kudzai Chikede Dabiao Chen Dabiao Chen Dabiao Chen Ziying Lei Ziying Lei Ziying Lei Zhiliang Gao Zhiliang Gao Zhiliang Gao Qian Zhang Qiaoxia Tong |
| author_sort | Peipei Wang |
| collection | DOAJ |
| description | BackgroundKnowing about cytokine profile contributes to clarify the underling immune mechanism of HBsAg seroclearance rate increase. This study aims to investigate cytokine changes during nucleos(t)ide analogues (NAs) and peginterferon-α (Peg-IFNα) therapy and their impact on the HBsAg serologic response.MethodsA total of 78 HBV DNA-negative chronic Hepatitis B (CHB) patients were studied after a lead-in phase of NAs with complete serum cytokines. Serum cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-α) were quantified by flow cytometry (FCM) every 24 weeks, before, during and at the end of NAs and Peg-IFNα treatment. Clinical and laboratory data were also taken at the same time. Analysis was performed between cured and uncured groups characterized by HBsAg seroclearance. PBMCs samples from five patients (two in cured group and three in uncured group) were analyzed by FCM.ResultsHBsAg seroclearance was achieved in 30 (38,5%) patients defined as the cured group. In comparison to uncured individuals, cured patients showed similar expressions of serum IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-α during the treatment of NAs and Peg-IFNα. Compared with the uncured groups, IL-5 was remarkably increased in cured patients. IL-5 at weeks 24 and 48 were associated with HBsAg seroconversion (p=0.033 and 0.027, respectively). PBMCs sample analysis confirmed the predicted value of IL-5 in response to NAs and Peg-IFNα treatment.ConclusionsIL-5 at weeks 24 and 48 might be used as a biomarker for HBsAg seroclearance in NAs-experienced CHB patients treated with NAs combined with Peg-IFNα. More importantly, exploiting the expression of this cytokine may help to develop a better understanding of the immune pathogenesis of chronic HBV infection. |
| first_indexed | 2024-04-11T00:52:57Z |
| format | Article |
| id | doaj.art-1e180699f8ec4e168702ebba0913ca70 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T00:52:57Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1e180699f8ec4e168702ebba0913ca702023-01-05T08:00:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.11043291104329Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferonPeipei Wang0Peipei Wang1Peipei Wang2Zhishuo Mo3Zhishuo Mo4Zhishuo Mo5Ying Zhang6Ying Zhang7Ying Zhang8Chunxia Guo9Trevor Kudzai Chikede10Dabiao Chen11Dabiao Chen12Dabiao Chen13Ziying Lei14Ziying Lei15Ziying Lei16Zhiliang Gao17Zhiliang Gao18Zhiliang Gao19Qian Zhang20Qiaoxia Tong21Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, ChinaGuangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaKey Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou, Guangdong, ChinaDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaBackgroundKnowing about cytokine profile contributes to clarify the underling immune mechanism of HBsAg seroclearance rate increase. This study aims to investigate cytokine changes during nucleos(t)ide analogues (NAs) and peginterferon-α (Peg-IFNα) therapy and their impact on the HBsAg serologic response.MethodsA total of 78 HBV DNA-negative chronic Hepatitis B (CHB) patients were studied after a lead-in phase of NAs with complete serum cytokines. Serum cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-α) were quantified by flow cytometry (FCM) every 24 weeks, before, during and at the end of NAs and Peg-IFNα treatment. Clinical and laboratory data were also taken at the same time. Analysis was performed between cured and uncured groups characterized by HBsAg seroclearance. PBMCs samples from five patients (two in cured group and three in uncured group) were analyzed by FCM.ResultsHBsAg seroclearance was achieved in 30 (38,5%) patients defined as the cured group. In comparison to uncured individuals, cured patients showed similar expressions of serum IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17 and TNF-α during the treatment of NAs and Peg-IFNα. Compared with the uncured groups, IL-5 was remarkably increased in cured patients. IL-5 at weeks 24 and 48 were associated with HBsAg seroconversion (p=0.033 and 0.027, respectively). PBMCs sample analysis confirmed the predicted value of IL-5 in response to NAs and Peg-IFNα treatment.ConclusionsIL-5 at weeks 24 and 48 might be used as a biomarker for HBsAg seroclearance in NAs-experienced CHB patients treated with NAs combined with Peg-IFNα. More importantly, exploiting the expression of this cytokine may help to develop a better understanding of the immune pathogenesis of chronic HBV infection.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1104329/fullIL-5HBsAg seroclearancecytokinespegylated interferonnucleos(t)ide analogues |
| spellingShingle | Peipei Wang Peipei Wang Peipei Wang Zhishuo Mo Zhishuo Mo Zhishuo Mo Ying Zhang Ying Zhang Ying Zhang Chunxia Guo Trevor Kudzai Chikede Dabiao Chen Dabiao Chen Dabiao Chen Ziying Lei Ziying Lei Ziying Lei Zhiliang Gao Zhiliang Gao Zhiliang Gao Qian Zhang Qiaoxia Tong Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon Frontiers in Immunology IL-5 HBsAg seroclearance cytokines pegylated interferon nucleos(t)ide analogues |
| title | Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon |
| title_full | Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon |
| title_fullStr | Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon |
| title_full_unstemmed | Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon |
| title_short | Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon |
| title_sort | serum il 5 levels predict hbsag seroclearance in patients treated with nucleos t ide analogues combined with pegylated interferon |
| topic | IL-5 HBsAg seroclearance cytokines pegylated interferon nucleos(t)ide analogues |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1104329/full |
| work_keys_str_mv | AT peipeiwang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT peipeiwang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT peipeiwang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT zhishuomo serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT zhishuomo serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT zhishuomo serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT yingzhang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT yingzhang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT yingzhang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT chunxiaguo serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT trevorkudzaichikede serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT dabiaochen serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT dabiaochen serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT dabiaochen serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT ziyinglei serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT ziyinglei serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT ziyinglei serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT zhilianggao serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT zhilianggao serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT zhilianggao serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT qianzhang serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon AT qiaoxiatong serumil5levelspredicthbsagseroclearanceinpatientstreatedwithnucleostideanaloguescombinedwithpegylatedinterferon |